Page last updated: 2024-12-10

2-(1,5-dimethyl-4-pyrazolyl)-4-quinolinecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(1,5-dimethyl-4-pyrazolyl)-4-quinolinecarboxylic acid, often abbreviated as **DMQ**, is a heterocyclic compound with a specific structure that makes it an interesting target for research. Here's a breakdown:

**Structure:**

* **Quinoline:** The core structure is a quinoline, a bicyclic aromatic ring system containing both benzene and pyridine rings.
* **Pyrazole:** Attached to the quinoline ring is a pyrazole, another heterocyclic ring system.
* **Substitutions:** The pyrazole ring has two methyl groups (CH3) at positions 1 and 5, and the quinoline ring has a carboxylic acid group (-COOH) at position 4.

**Importance in Research:**

DMQ is important because of its potential applications in various fields, including:

* **Medicinal Chemistry:**
* **Antimicrobial activity:** DMQ has shown promising antibacterial and antifungal activity against a range of microorganisms. This makes it a potential candidate for developing new antibiotics.
* **Anti-inflammatory activity:** Studies have shown that DMQ possesses anti-inflammatory properties, potentially beneficial for treating various inflammatory conditions.
* **Antioxidant activity:** DMQ has been reported to exhibit antioxidant activity, which could protect cells from damage caused by free radicals.
* **Material Science:**
* **Organic semiconductors:** DMQ's conjugated structure (alternating single and double bonds) makes it suitable for use in organic electronics as a building block for organic semiconductors. This opens possibilities for developing new and flexible electronic devices.
* **Luminescent materials:** DMQ's structure can also contribute to its luminescent properties, leading to applications in organic light-emitting diodes (OLEDs) and other optoelectronic devices.
* **Analytical Chemistry:**
* **Fluorescence probes:** DMQ's fluorescent properties can be exploited for developing sensors and probes for detecting specific molecules or ions in biological and environmental samples.

**Current Research:**

Researchers are actively investigating DMQ's properties and potential applications further. This includes:

* **Synthesizing new derivatives:** Modifying DMQ's structure to create new derivatives with enhanced biological activity or different optical properties.
* **Understanding its mechanism of action:** Studying how DMQ interacts with biological targets to understand its biological effects.
* **Developing new applications:** Exploring novel uses for DMQ, such as in drug delivery systems or bioimaging techniques.

**Overall, 2-(1,5-dimethyl-4-pyrazolyl)-4-quinolinecarboxylic acid (DMQ) is a promising molecule with potential applications in diverse fields. Ongoing research will further clarify its properties and pave the way for developing innovative technologies and treatments.**

Cross-References

ID SourceID
PubMed CID3164943
CHEMBL ID1599774
CHEBI ID120051

Synonyms (22)

Synonym
MLS000715100
smr000275079
2-(1,5-dimethyl-1h-pyrazol-4-yl)quinoline-4-carboxylic acid
STK310122
2-(1,5-dimethyl-1h-pyrazol-4-yl)-quinoline-4-carboxylic acid
CHEBI:120051
AKOS000302471
2-(1,5-dimethylpyrazol-4-yl)quinoline-4-carboxylic acid
HMS2703E05
BBL013056
925145-52-4
2-(1,5-dimethyl-1 h-pyrazol-4-yl)-quinoline-4-carboxylic acid
CHEMBL1599774
Q27207853
2-(1,5-dimethyl-4-pyrazolyl)-4-quinolinecarboxylic acid
mfcd04969957
VS-03651
2-(1,5-dimethyl-1h-pyrazol-4-yl)quinoline-4-carboxylicacid
EN300-229688
CS-0240687
DTXSID801325186
2-(1,5-dimethyl-1h-pyrazol-4-yl)-4-quinolinecarboxylic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency28.18380.100020.879379.4328AID588456
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency44.66840.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]